comparemela.com

Latest Breaking News On - Petosemtamab peto - Page 1 : comparemela.com

Merus Announces Financial Results for the Second Quarter and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

ChinaUnited statesCambridgeCambridgeshireUnited kingdomMeruXizangNetherlandsAmericanZenocutuzumab zenoPetosemtamab petoAmerican society of clinical oncologyDrug administrationEarly access programExchange commissionAstrazeneca

Merus N.V.: Merus Announces Financial Results for the Second Quarter and Provides Business Update

- Clinical update of zenocutuzumab (Zeno) presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Zeno represents a potential new standard of care for NRG1+ cancer -

ChinaUnited statesCambridgeCambridgeshireUnited kingdomMeruXizangNetherlandsAmericanZenocutuzumab zenoPetosemtamab petoExchange commissionAstrazenecaAmerican society of clinical oncologyBetta pharmaceuticals coDrug administration

Merus N.V.: Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

- Zenocutuzumab clinical abstract selected for oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting- Company to host investor call on Sunday, June 5 at 6:00 p.m.

ChinaUnited statesCambridgeCambridgeshireUnited kingdomMeruXizangNetherlandsAmericanZenocutuzumab zenoPetosemtamab petoIncyteAlison schramCompany biclonicsAmerican society of clinical oncologyEarly access program

Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

ChinaUnited statesCambridgeCambridgeshireUnited kingdomMeruXizangNetherlandsAmericanZenocutuzumab zenoPetosemtamab petoIncyteAlison schramCompany biclonicsAmerican society of clinical oncologyEarly access program

2022-05-09 | NDAQ:MRUS | Press Release

(2022-05-09 | NDAQ:MRUS) Merus Announces Financial Results for the First Quarter 2022 and Provides Business Update

ChinaUnited statesCambridgeCambridgeshireUnited kingdomNetherlandsAmericanZenocutuzumab zenoIncyte closecurlyquotePetosemtamab petoBayer closecurlyquoteAlison schramNovartis closecurlyquoteAmerican society of clinical oncologyEarly access programKathleen farren merusnv communications specialist

vimarsana © 2020. All Rights Reserved.